Celyad Oncology SA ADR (CYAD) stock is down -19.32% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives CYAD stock a score of 32 out of a possible 100.
That rank is primarily influenced by a long-term technical score of 3. CYAD's rank also includes a short-term technical score of 5. The fundamental score for CYAD is 89. In addition to the average rating from Wall Street analysts, CYAD stock has a mean target price of 18. This means analysts expect the stock to climb 153.52% over the next 12 months.
What's Happening with CYAD Stock Today
Celyad Oncology SA ADR (CYAD) stock is trading at $7.10 as of 1:12 PM on Monday, Apr 12, a rise of $0.14, or 2.01% from the previous closing price of $6.96. Volume today is above average. So far 51,130 shares have traded compared to average volume of 14,295 shares. The stock has traded between $7.00 and $7.20 so far today.
Click Here to get the full Stock Score Report on Celyad Oncology SA ADR (CYAD) Stock.
